6634.Two
6634.TWO operates in the healthcare diagnostics segment, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. 6634.TWO operates in the healthcare diagnostics segment, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6634.TWO operates in the healthcare diagnostics segment, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company exhibits a highly leveraged equity structure, with a debt-to-equity ratio of 0.01, indicating minimal reliance on debt financing. However, the company's liquidity position is characterized as medium risk, with a current ratio of 42.27, suggesting a strong short-term liquidity buffer. Despite this, the company reported negative operating cash flow of -95.299 million TWD and free cash flow of -106.286 million TWD, indicating ongoing cash outflows from operations.
Profitability metrics are severely negative, with a return on equity of -11.34% and a return on assets of -10.97%, both significantly below the industry median for biotechnology and medical research firms. These figures suggest the company is not generating returns that meet the cost of capital or asset efficiency benchmarks.
The company's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or segment concentration risk. However, the lack of diversification in revenue sources could pose a risk if the company's primary market or product experiences a downturn.
The company's growth trajectory is unclear due to the absence of forward-looking guidance in the provided data. Historical revenue of 47,000 million TWD does not provide a clear indication of growth or contraction, and the company's negative operating and net income figures suggest operational challenges that could impede future growth.
The company's risk profile is marked by medium liquidity risk and low dilution potential. The negative net cash position after subtracting total debt is a key flag, indicating potential pressure to secure additional financing. The company has not disclosed any recent dilutive events, and the diluted shares outstanding are equal to the basic shares, suggesting no near-term dilution risk.
Recent events, including filings and transcripts, are not detailed in the available data, limiting the ability to assess the company's strategic direction or management commentary. The absence of recent disclosures may indicate a lack of material developments or a limited public presence.
- The company has a strong liquidity position as indicated by a high current ratio, but it is experiencing negative cash flows from operations.
- Profitability is significantly negative, with both return on equity and return on assets well below industry norms.
- The company's financial structure is heavily equity-based, with minimal debt, but it is not generating positive returns on its assets or equity.
- There is no clear indication of geographic or segment diversification, which could increase exposure to market-specific risks.
- The company's growth trajectory is uncertain due to the lack of forward-looking guidance and negative financial performance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6634.TWO Market data — financials · 2026-05-27